Rhythm Biosciences Ltd. (AU:RHY) has released an update.
Rhythm Biosciences Limited, an innovative Australian medical diagnostics company, has presented its financial report for the year ended 30 June 2024. The company, known for its pioneering work in developing affordable cancer blood tests, is on the cusp of commercializing its ColoSTAT® product for early colorectal cancer detection. The report also details the active engagement of its directors throughout the financial year.
For further insights into AU:RHY stock, check out TipRanks’ Stock Analysis page.
